Search Within

Andrew D Seidman

  1. "Cardiology"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (2)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (5)
  2. Breast Medicine Service (5)
  3. Cardiology (5)
  4. Department of Medicine (5)
  5. Division of Subspecialty Medicine (5)
  6. Solid Tumor Oncology Division (5)

More Groups

People
  1. Chau Dang (5)
  2. Clifford Hudis (5)
  3. Diana Lake (5)
  4. Larry Norton (5)
  5. Maura Dickler (5)
  6. Gabriella D'Andrea-Carlino (4)

More People

Years
  1. 2011 (1)
  2. 2009 (1)
  3. 2008 (2)
  4. 2006 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Breast Cancer Research and Treatment (1)
  3. Cancer Research (1)
  4. Clinical Cancer Research (1)
Publishers
  1. American Association for Cancer Research (2)
  2. American Society of Clinical Oncology (2)
  3. Springer (1)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Journal Article

    Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C. T.; Lin, N. U.; Lake, D.; Dickler, M. N.; Modi, S.; Seidman, A. D.; Steingart, R. M.; Norton, L.; Winer, E. P.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; George, R.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save